QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2354|24|3|436-443

ISSN： 0961-5423

Source： EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol.24, Iss.3, 2015-05, pp. : 436-443

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States

By Schwartzberg Lee   Morrow Gary   Balu Sanjeev   Craver Chris   Gayle Julie   Cox David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1613-1622

Informa Healthcare

Access to resources Recommend Favorite

Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 193-201

Bentham Science Publishers

Access to resources Recommend Favorite

Aprepitant as Salvage Therapy in Patients with Chemotherapy-Induced Nausea and Emesis Refractory to Prophylaxis with 5-HT3 Antagonists and Dexamethasone

By  

Oncology Research and Treatment, Vol. 29, Iss. 12, 2006-12 ,pp. : 557-561

Karger

Access to resources Recommend Favorite

Does previous chemotherapy‐induced nausea and vomiting predict postoperative nausea and vomiting?

By  

ACTA ANAESTHESIOLOGICA SCANDINAVICA, Vol. 59, Iss. 9, 2015-10 ,pp. : 1145-1153

John Wiley & Sons Inc

Access to resources Recommend Favorite

5-HT3-Receptor Antagonists in the Management of Nausea and Vomiting in Cancer and Cancer Treatment

By  

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 97-109

Karger

Access to resources Recommend Favorite